In July 2018, KM Biologics succeeded Kaketsuken’s main businesses and joined the Meiji Group. Under the Meiji Group, which has contributed to health for over 100 years through its food and pharmaceutical units, KM Biologics' mission is to create unique value that is one step ahead as a prevention and treatment professional.
In recent years, as new threats of infectious diseases have become a social issue, KM Biologics is aspiring to pursue the possibilities of biotechnology more than ever and contribute to solving social issues, utilizing its research, development and manufacturing technologies for vaccines and plasma-derived therapies. Furthermore, we believe that we can contribute to public health and people's health through synergies created by boosting integrated management with Meiji Seika Pharma and combining the technological capabilities and knowledge of both companies.
Nowadays, the social issues surrounding us are changing dramatically, becoming more complex and uncertain. In order to achieve continuous growth over the long term in such environment, it is important for us not only to expand the scale of the business, but also how to solve social issues through our business activities. We aim to realize a society where people around the world can live in good health and peace of mind by accelerating our business and sustainability activities and having each employee embody the group slogan, "Now ideas for wellness".